<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687646</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-EICH-2014</org_study_id>
    <secondary_id>2014-005533-32</secondary_id>
    <nct_id>NCT02687646</nct_id>
  </id_info>
  <brief_title>Clinical Trial With MSC for Graft Versus Host Disease Treatment</brief_title>
  <official_title>Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andalusian Initiative for Advanced Therapies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sequential administration of MSCs obtained from adipose tissue is an effective and safe
      treatment for acute graft versus host disease refractory to first-line treatment. Furthermore
      the infusion of these cells produces a biological pattern in patients that relates to the
      clinical response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, open, non -controlled clinical trial. It is a phase I-II trial to assess the
      safety and efficacy of sequential infusion of allogeneic MSCs from adipose tissue, expanded
      &quot;in vitro&quot; platelet lysate in the treatment of patients undergoing hematopoietic stem cell
      trasplantation, who have developed a refractory graft versus host disease to first line of
      treatment.

      This is a prospective, multicenter, open to patients undergoing allogeneic transplantation in
      Spanish hospitals, with one cohort of patients who receive four sequential doses of MSC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by incidence of serious adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety will be measured in terms of:
Incidence of Serious Adverse Events after at the time of the infusion of study drug or during follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Effectiveness will be measured in terms of:
Answer of refractory acute graft disease against host to first-line treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Allogeneic Mesenchymal Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adult Allogeneic Mesenchymal cells from adipose tissue.</intervention_name>
    <description>Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.
Subjects will receive four sequential IV dose of Mesenchymal stem cells.
Sequential doses:
Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg</description>
    <arm_group_label>Allogeneic Mesenchymal Cells</arm_group_label>
    <other_name>MSC for the treatment of graft -versus -host disease</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of ≥ grade II Graft Versus Host Disease refractory to first-line treatment.

          2. Having been subjected to hematopoietic Stem Cell Transplantation as treatment for
             malignant blood disorder has been controlled by the transplantation. The source may
             have been bone marrow cells or peripheral blood (PB) and coming from a family member
             or unrelated donor.

          3. Having been transplanted with myeloablative or non-myeloablative conditioning.

          4. normal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension,
             congestive heart failure, angina pectoris or myocardial infarction within 6 months
             prior to the process

          5. Lung function without evidence of severe obstructive or restrictive lung disease.

          6. Age between 18 and 65 years.

          7. Women of childbearing age considered until one year after the last menstrual period
             and which have not undergone a surgical sterilization must obtain a negative pregnancy
             test at the time of inclusion in the study and commit to use a medically approved
             birth control while on study.

          8. normal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension,
             congestive heart failure, angina pectoris or myocardial infarction within 6 months
             prior to the process.

          9. Signature of informed consent -

        Exclusion Criteria:

          1. uncontrolled blood disorder by transplantation or progression at the time of
             inclusion.

          2. bacterial, viral, fungal or is not being controlled.

          3. Any circumstance that the proposed trial dissuade medical treatment. Pregnancy,
             lactation or refusal to use safe contraceptive measures.

          4. Patients who are currently participating or have completed their participation in a
             clinical trial in less than 3 months or who have participated in a clinical trial of
             Advanced Therapies at any previous time period.

          5. Patients who are currently participating or have completed their participation in a
             clinical trial in a period shorter than 3 months or who have participated in a
             clinical trial of Advanced Therapies at any previous time.

          6. positive serology for Hepatitis B , Hepatitis C and AIDS Virus. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Caballero, Hematologist</last_name>
    <role>Study Director</role>
    <affiliation>Virgen del Rocio University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Caballero Velazquez, Hematologist</last_name>
    <phone>+34 955 013256</phone>
    <email>t.c.velazquez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Cardesa Gil, Chemistry</last_name>
    <phone>+34 955048366</phone>
    <email>ana.cardesa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra, Av Pio XII ,36</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Rodriguez Otero, Hematologist</last_name>
      <phone>+34 948 296 397</phone>
      <email>paurodriguez@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Felipe Prosper, Chief of Hematology</last_name>
      <email>fprosper@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Rodriguez Otero, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Andreu, Biologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Prosper, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Rifont Roca, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Concepción Herrera Arroyo, MD</last_name>
      <email>inmaculada.herrera.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Inmaculada Concepción Herrera Arroyo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Martín Calvo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Rojas Contreras</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estefanía García Torres</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Blanquer Blanquer, MD</last_name>
      <email>miguelblanquer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Blanquer Blanquer</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose María Moraleda Jiménez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrés Sánchez Salinas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Montserrat Coll</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana García Hernández</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darío Sánchez Slinas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Algueró Martín</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Iniesta Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Ángeles Cuesta Casas, MD</last_name>
      <email>cuestamarian@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mª Ángeles Cuesta Casas</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Contento Gonzalo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Vidales Mancha</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MªJesús Pascual Gascón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital clinico universitario de salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Lopez Corral, Hematologist</last_name>
      <phone>+34 923 291316</phone>
      <email>lucialopezcorral@usal.es</email>
    </contact>
    <contact_backup>
      <last_name>Consuelo Del Cañizo, Chief of Hematology</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lucia Lopez Corral, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Prosper, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lourdes Vazquez, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mª Dolores Caballlero, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alba Redondo, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fermin Sanchez Guijo, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Lopez Villar, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocio University Hospital, av. Manuel Siurot s/n</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Caballero Velazquez, Chief of Hematology</last_name>
      <phone>955 013256</phone>
      <email>t.c.velazquez@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jose Antonio Perez Simon, Hematogist</last_name>
      <phone>955 01 32 60</phone>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Teresa Caballero Velazquez, Hematologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Antonio Perez Simon, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Calderon Cabrera, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Montero Cuadrado, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Alvarez Laderas, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estefania Garcia Guerrero, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estrella Carrillo, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosario Morales, Hematologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

